Related Experiment Video
Updated: Aug 6, 2026
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Predictive Ability of the CHA2DS2-VA Score for No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Patients
Ying Sun1, Jian Ren1,2, Wei Wang1
1Department of Cardiology, Liaocheng People's Hospital Affiliated to Shandong First Medical University, Liaocheng, Shandong, People's Republic of China.
Insights
The CHA2DS2-VA (CV) score predicts the no-reflow phenomenon (NRP) in ST-elevation myocardial infarction (STEMI) patients undergoing PCI, but its effectiveness is sex-specific. The CV score is a valuable tool for predicting NRP in female STEMI patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Clinical Risk Stratification
Background:
- The no-reflow phenomenon (NRP) is a common complication following primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
- Accurate prediction of NRP is crucial for optimizing patient management and outcomes after STEMI.
- The CHA2DS2-VA score (CV score) is a clinical risk assessment tool that may have predictive value for NRP.
Purpose of the Study:
- To evaluate the CHA2DS2-VA score (CV score) as a predictor of the no-reflow phenomenon (NRP) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
- To investigate potential sex differences in the predictive ability of the CV score for NRP.
Main Methods:
- Retrospective analysis of 725 STEMI patients undergoing primary PCI.
- Stratification of patients based on the median CV score (≤2 vs. >2).
- Assessment of the CV score's predictive ability using logistic regression, receiver operating characteristic (ROC) analysis, and DeLong tests, with a focus on sex-specific effects.
Main Results:
- Higher NRP incidence was observed in patients with a high CV score (15.2% vs. 8.7%, p=0.007).
- The CV score significantly predicted NRP overall (adjusted OR: 1.295, p=0.002) and specifically in females (AOR: 1.597, p=0.002), but not in males.
- The area under the curve (AUC) for predicting NRP was 0.613 in all patients and 0.673 in females, indicating a significant sex-specific predictive value (sex × CV score interaction, p=0.017).
Conclusions:
- The CHA2DS2-VA score demonstrates sex-specific predictive value for NRP in STEMI patients.
- The CV score is a valuable predictor of NRP in female STEMI patients but not in males.
- A tailored risk stratification approach is recommended, utilizing the CV score alone for females and integrating laboratory/procedural markers for males.
Background:
No-reflow phenomenon (NRP) frequently complicates ST-elevation myocardial infarction (STEMI). This study evaluated the CHA2DS2-VA score (CV score) as a predictor of NRP in STEMI patients undergoing primary PCI.
Methods:
A total of 725 STEMI patients were retrospectively enrolled and stratified by median of CV score (≤ 2 vs. > 2). The predictive ability of the CV score for NRP was assessed using logistic regression, receiver operating characteristic analysis, and DeLong tests.
Results:
NRP incidence was higher in the high CV score group (15.2% vs. 8.7%, p = 0.007). The CV score predicted NRP overall (adjusted OR: 1.295, p = 0.002), but this effect was confined to females (AOR: 1.597, p = 0.002), with no significant association in males. Area under the curve value (AUC) of the CV score for predicting NRP was 0.613 in all patients (38.8% sensitivity and 79.1% specificity, p = 0.001) and 0.673 in females (78.1% sensitivity and 47.6% specificity, p = 0.002). A significant sex × CV score interaction (p = 0.017) confirmed sex-modified predictive value. DeLong tests combining the CV score with laboratory markers improved prediction in males but not females.
Conclusion:
The CV score is a sex-specific predictor of NRP in STEMI, with predictive value in females but not males. These findings support a tailored risk stratification approach: using the CV score alone for female patients, while integrating laboratory and procedural markers for male patients.
